Compare Biogen Inc (BIIB) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs PPG Industries, Inc. — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while PPG Industries, Inc. trades at $114.66 (market cap $25.56B). The key difference: Biogen Inc and PPG Industries, Inc. are close in size by market cap, and PPG Industries, Inc. pays a 2.48% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | PPG | |
|---|---|---|
Market Cap | $28.34B | $25.56B |
Sector | Health | Basic Materials |
52-Week High | $216.63 | $131.56 |
52-Week Low | $122.68 | $94.34 |
Enterprise Value | $30.62B | $31.66B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
PPG Industries trades at $113.84, down 2.5% on the day, with a bullish technical signal despite near-term volatility. The stock shows strong profitability with a net margin of 9.83% and ROE of 21.09%, supported by consistent earnings beats in recent quarters. Recent news highlights innovation in aerospace and marine coatings, alongside a sustainable dividend profile. Valuation ratios appear reasonable with a P/E of 16.31 and P/S of 1.6.
The outlook remains positive given analyst consensus favoring a buy rating and a $131.75 price target, implying significant upside. Risks include volume softness and margin pressure, but robust cash flow and strategic innovations provide a cushion. The stock presents a value opportunity with growth catalysts from new product launches and market expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
